The autism-associated gene chromodomain helicase DNA-binding protein 8 (CHD8) regulates noncoding RNAs and autism-related genes

B Wilkinson1, N Grepo2, BL Thompson3, J Kim2,4, K Wang2,4, OV Evgrafov2,4, W Lu5,6, JA Knowles2,4 and DB Campbell2,4

Chromodomain helicase DNA-binding protein 8 (CHD8) was identified as a leading autism spectrum disorder (ASD) candidate gene by whole-exome sequencing and subsequent targeted-sequencing studies. De novo loss-of-function mutations were identified in 12 individuals with ASD and zero controls, accounting for a highly significant association. Small interfering RNA-mediated knockdown of CHD8 in human neural progenitor cells followed by RNA sequencing revealed that CHD8 insufficiency results in altered expression of 1715 genes, including both protein-coding and noncoding RNAs. Among the 10 most changed transcripts, 4 (40%) were noncoding RNAs. The transcriptional changes among protein-coding genes involved a highly interconnected network of genes that are enriched in neuronal development and in previously identified ASD candidate genes. These results suggest that CHD8 insufficiency may be a central hub in neuronal development and ASD risk.

Translational Psychiatry (2015) 5, e568; doi:10.1038/tp.2015.62; published online 19 May 2015

INTRODUCTION

Autism spectrum disorder (ASD) is a complex neurodevelopmental disorder characterized by impairments in social interaction, communication and behavioral flexibility.1 Due to the vast clinical and genetic heterogeneity of ASD, the identification of causal genetic determinants has proven challenging.2-4 However, multiple independent studies have now provided substantial evidence for the contribution of de novo loss-of-function (LoF) mutations in chromodomain helicase DNA-binding protein 8 (CHD8) to ASD.5-9 Initially, exome sequencing on 209 ASD probands and their unaffected family members discovered two de novo LoF mutations in CHD8.6 Subsequent targeted sequencing of 44 candidate genes in 2446 ASD probands identified an additional seven de novo LoF mutations in CHD8, establishing a frequency of mutation that is the highest of all genes screened.7 Furthermore, a second targeted-sequencing study of an additional 3370 children with ASD or developmental delay identified three de novo LoF mutations in CHD8.8 Altogether, these highly significant findings have placed CHD8 as a genuine ASD risk factor and account for 0.2% (12/6,176) of ASD cases. The CHD8 LoF mutations have been found throughout the coding region of the gene, with truncating mutations as early as amino acid 62 of the 2581 amino acid CHD8 protein. Truncating mutations were found in the chromodomain, the dex domain and the helicase domain. A detailed map of all the identified CHD8 LoF mutations was published recently.9 In addition to de novo mutations in CHD8, six potentially disrupting mutations with unknown or inherited modes of transmission have also been identified8,9 along with a balanced chromosomal abnormality leading to disruption of CHD8.10 CHD8 LoF mutations have not been found in any of the 8792 controls included in these analyses, emphasizing the impact of CHD8 LoF mutations on ASD risk.9 Phenotypic characterization of individuals with CHD8 disrupting mutations indicate a subset of ASD that includes macrocephaly, distinct facial features and gastrointestinal difficulties.8

Although a critical role of CHD8 in development is revealed by the embryonic lethality of Chd8 knockout mice,11 the function of CHD8 in neural cell lineages has been largely unexplored. As CHD8 actively associates with core transcriptional machinery,12 transcription factors13,14 and histone-modifying complexes,15 transcriptional dysregulation conferred by CHD8 insufficiency may provide evidence for the neurodevelopmental phenotypes observed in ASD. To emulate the potential effects of the identified LoF mutations, we performed small interfering RNA (siRNA)-mediated knockdown of CHD8 followed by genome-wide transcriptional profiling through RNA sequencing (RNA-seq). Here, we show that knockdown of CHD8 in SK-N-SH human neural progenitor cells results in altered expression of a highly interconnected network of genes, which are enriched in several processes essential for neuronal development. Remarkably, numerous previously identified ASD candidate genes are also differentially expressed in response to knockdown of CHD8, suggesting a convergence of multiple genes contributing to ASD onset. The data presented here point toward a role of CHD8 in maintaining the active transcription of neural-specific genes and begins to elucidate the potential contributions of decreased functional CHD8 to the pathogenesis of ASD.

E-mail: dbcampbe@med.usc.edu
Received 29 October 2014; revised 12 February 2015; accepted 31 March 2015

1Development, Stem Cells, and Regeneration Ph.D. Program, University of Southern California, Los Angeles, CA, USA; 2Zilkha Neurogenetic Institute, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA; 3Division of Occupational Science and Occupational Therapy, Herman Ostrow School of Dentistry, University of Southern California, Los Angeles, CA, USA. Correspondence: Dr DB Campbell, Keck School of Medicine, University of Southern California, 213 Zilkha Neurogenetic Institute, 1501 San Pablo Street, Los Angeles, CA 90089, USA.
MATERIALS AND METHODS

Cell culture
To measure gene expression in human neural progenitor cells, SK-N-SH cells (American Type Culture Collection; Manassas, VA, USA) were maintained in minimal essential medium supplemented with 10% heat-inactivated fetal bovine serum, 1% penicillin/streptomycin, non-essential amino acids, and 1.5 g l⁻¹ sodium bicarbonate in 183-cm flasks at 37 °C and 5% CO₂.

siRNA transfection
To determine the impact of CHD8 knockdown on gene expression in human neural progenitor cells, SK-N-SH cells were seeded into six-well 10-cm plates and grown for 24 h (~70% confluency) before transfection. Transfections were carried out with either siRNA silencer select negative control No. 1 (catalog no. 4390843, Ambion/Life Technologies; Carlsbad, CA, USA) or siRNA targeting CHD8 (catalog no. 33582, Ambion/Life Technologies) at a concentration of 20 nM using Lipofectamine RNAiMAX Reagent (Invitrogen/Life Technologies; Carlsbad, CA, USA) according to the manufacturer’s protocol. Cells were then collected 72 h post siRNA transfection and processed for downstream applications. Experiments were performed in quadruplicate.

Western blot analyses
To determine the degree to which siRNA knockdown of CHD8 transcript results in decreased CHD8 protein, total protein was isolated using the Illustra triplePrep kit (GE Healthcare; Waukesha, WI, USA) and protein concentration was determined using the DC protein assay (Bio-Rad; Hercules, CA, USA). Total protein (10 μg) was then separated on a 4–20% gradient criterion TGX gel (Bio-Rad) and transferred to a nitrocellulose membrane by capillary transfer at 80 V for 3 h using a Bio-Rad Criterion Transflective Western Blotting System. Blots were incubated overnight at 4 °C with anti-CHD8 (catalog no. 7656, Cell Signaling Technology; Danvers, MA, USA) and anti-GAPDH (catalog no. 1228, Cell Signaling Technology) primary antibodies diluted 1:1000 in blocking buffer. Anti-rabbit immunoglobulin G, horseradish-peroxidase-linked secondary antibody (catalog no. 7074, Cell Signaling Technology) was diluted 1:2000 and incubated with the membrane for 1.5 h at room temperature. Signal was developed using SuperSignal West Dura Extended Duration Substrate (Thermo Fisher Scientific; Waltham, MA, USA) and captured on a BioSpectrum Imaging System (UVP; Upland, CA, USA). The total density ratio of CHD8 to GAPDH was determined using the VisionWorks LS version 6.8 software (UVP) and analyzed by Student’s paired t-test for comparison (n = 4).

RNA-seq
To determine genes that are differentially expressed in response to knockdown of CHD8 on a genome-wide scale, cells were homogenized with QiAshredder spin columns (Qiagen; Valencia, CA, USA) followed by total cellular RNA extraction using the Qiagen RNeasy kit according to the manufacturer’s protocol. RNeasy extraction typically excludes fragments < 200 bp. Therefore, the data presented here focuses on long noncoding RNAs (ncRNAs). Quality (RNA integrity number) was assessed using an Agilent Technologies 2200 TapeStation Instrument (Agilent Technologies; Santa Clara, CA, USA) and 260/280 absorbance ratios were obtained using the NanoDrop ND-1000 Spectrophotometer (Thermo Fisher Scientific). cDNA library preparation was carried out using the Illumina TrueSeq Stranded Total RNA Sample Preparation kit and sequencing was performed on the HiSeq2000 sequencer to generate 101 bp single-end reads (Illumina; San Diego, CA, USA). An approximate average of 45 million reads per replicate was obtained for samples treated with siRNA targeting CHD8 and an average of 40 million reads per replicate was obtained for samples treated with negative control siRNA (Supplementary Table 1).

RNA-seq analysis
Quality control pre-processing of raw reads was carried out using Cutadapt.17 Reads were first mapped to the transcriptome of either UCSC Hg19 or ENSEMBL GrCh37 release 75 and the remaining reads were then mapped to the unannotated regions of the respective human genome build using Tophat.18 The percentage of reads that were aligned to the genome for each replicate along with their respective quality control metrics are outlined in Supplementary Table 1. Following alignment, differential gene expression analysis was carried out using Cuffdiff19 along with a supplied GTF file of the corresponding transcriptome to be analyzed. Cuffdiff analysis was performed with default settings with the exception of the masking of all annotated ribosomal RNAs and the no-effective-length-correction option, which was used to reduce over-estimation of short transcript expression. Genes with a false discovery rate (Q-value) of < 0.05 were considered significant. All gene ontology (GO) and protein–protein interaction analyses were carried out using the list of significantly differentially expressed genes identified using the UCSC Hg19. A genome annotation. To explore changes in genes transcribing ncRNAs, we also carried out the RNA-seq analysis using the ENSEMBL GrCh37. Release 75, gene annotation, which contains a much larger quantity of ncRNA transcripts compared with the UCSC Hg19 annotated transcriptome.

Quantitative PCR
To measure the degree to which siRNA knockdown of CHD8 results in decreased transcript levels and verify the quality of RNA-seq data analysis, cell pellets were processed for RNA isolation using the Qiagen RNeasy kit (Qiagen; Valencia, CA, USA). Reverse transcription was performed with Life Technologies Taqman Gene Expression qPCR kits on a Life Technologies OneStepPlus real-time PCR machine. Each sample was run in triplicate along with the housekeeping gene, GAPDH. Assays used for qPCR validation (Life Technologies) include ABCA1 (Hs01095181_m1), CHD8 (Hs00394229_m1), BDNF (Hs02178934_s1), CUL 1 (Hs01117001_m1), GAPDH (Hs9999905_g1), GAPDH (Hs00744845_s1), HMG2 (Hs00171569_s1), HSPB3 (Hs00937412_s1), IGFB3 (Hs00365742_g1), IL1R1 (Hs00991002_m1), IL6 (Hs0074103_m1), LINC00473 (Hs00293257_m1), LINC01021 (Hs01388363_m1), MMP3 (Hs00968305_m1), PITA3 (Hs01013933_g1), SCNV2 (Hs01109877_m1), SPP1 (Hs00117006_m1), SEMA3D (Hs00380877_m1), SYT2 (Hs00909223_m1), TGM2 (Hs00190278_m1) and TNS3 (Hs00994933_m1). Relative quantity of the assayed transcript was determined by the 2–ΔΔCt method using GAPDH as a reference.20 For RNA-seq validation, the observed qPCR changes were compared with those obtained in RNA-seq data analysis through the use of Spearman and Pearson correlation tests carried out in R statistical environment using the (cor.test) package.

Functional annotation and network construction
To begin to functionally characterize and cluster the differentially expressed transcripts, the Database for Annotation, Visualization and Integrated Discovery (DAVID)21 was used to determine direct interactions and connectivity among the protein products of the differentially expressed genes using the default settings. Network construction of the resulting interactions was carried out using Cytoscape version 3.1.1 software.22

ASD candidate genes statistical analysis
To analyze whether or not a lack of functional CHD8 results in decreased CHD8 expression. the Database for Annotation, Visualization and Integrated Discovery (DAVID)21 was used to determine direct interactions and connectivity among the protein products of the differentially expressed genes using the default settings. Network construction of the resulting interactions was carried out using Cytoscape version 3.1.1 software.23

RESULTS
Quantitative modeling of CHD8 de novo loss-of-function mutations
The ASD-associated CHD8 de novo LoF mutations likely result in an ~ 50% reduction in CHD8 transcript and CHD8 protein in the developing brains of individuals with ASD. To quantitatively model these dosage-dependent consequences of CHD8 LoF mutations, siRNA-mediated knockdown of CHD8 was performed in the
human neural progenitor cell line, SK-N-SH. Following this, the knockdown efficiency of both CHD8 transcript and CHD8 protein levels were confirmed via qPCR and western blotting, respectively (Figure 1).

CHD8 insufficiency results in genome-wide transcriptional changes

As transcriptional changes due to CHD8 insufficiency may be able to inform the mechanisms by which a lack of CHD8 influences ASD pathogenesis, we performed genome-wide transcriptome profiling of CHD8-depleted human neuronal progenitor cells, SK-N-SH, via RNA-seq. Differential gene expression analysis using the UCSC Hg19 genome annotation revealed 1715 differentially expressed genes (Supplementary Tables 2 and 3), with a majority of protein-coding genes downregulated (~63%). Subsequent qPCR validation was performed for genes categorized as either having large fold changes in expression or possessing functions related to neurodevelopmental processes identified by GO analysis. Comparison of gene expression levels measured by RNA-Seq and qPCR indicated a highly significant Pearson correlation coefficient (Figure 2), validating the magnitude of gene expression changes identified by RNA-seq. Both protein-coding and ncRNAs with altered expression are distributed across the genome in a pattern consistent with length of the chromosome; there does not appear to be any clustering of the genes with altered expression (Supplementary Figures 1 and 2).

Loss of functional CHD8 affects numerous ASD susceptibility genes

Comparing the list of differentially expressed genes to those genes contained in the SFARI AutDB gene database, there is an overlap of 65 genes excluding CHD8 (Supplementary Table 6). Of the 631 genes in the AutDB database, 409 were expressed in SK-N-SH cells. Among the 1715 genes differentially expressed following CHD8 knockdown in SK-N-SH cells, 65 were overlapping (Supplementary Table 7). Although the entire list of differentially expressed genes does not reach statistical significance for enrichment (P = 0.059, OR (odds ratio) = 1.307, Fisher’s exact test), considering only those genes that are downregulated significantly strengthens this enrichment (P = 4.793 × 10^{-3}, OR = 1.59). To focus on genes with substantial evidence for a role in ASD, a restricted list of 250 genes (159 of which are expressed in SK-N-SH cells) was curated from the SFARI database taking into account

Figure 1. Quantitative modeling of disruptive mutations in CHD8. (a) Quantitative PCR showed that a 20 nM concentration of CHD8 siRNA resulted in an ~ 50% reduction of CHD8 transcript. (b) Representative western blot indicated decreased CHD8 protein following CHD8 siRNA-mediated knockdown. (c) Quantitative analysis of western blot data shows a significant reduction in CHD8 protein following CHD8 siRNA treatment. Error bars are s.e.m., ***P < 0.01, *P < 0.05. CHD8, chromodomain helicase DNA-binding protein 8; siRNA, small interfering RNA.

Figure 2. qPCR validation of differentially expressed genes identified by RNA-Seq. Fifteen genes excluding CHD8 were assayed via qPCR to establish the validity of the differential expression analysis based on the obtained RNA-seq data. qPCR and RNA-seq values showed a statistically significant correlation with both Pearson and Spearman methods. qPCR, quantitative PCR.

CHD8 influences the expression of ncRNA

NcRNAs represent a relatively unexplored source of functional transcripts that may contribute to neurodevelopmental phenotypes. Using the ENSEMBL GrCh37, release 75, gene annotation, we identified 657 differentially expressed genes and found that ~ 12.5% of these were ncRNAs (Table 1, Supplementary Tables 4 and 5). The identified ncRNA account for 40% of the top 10 differentially expressed genes (Table 1). In contrast to protein-coding genes, the majority of ncRNAs are upregulated (~60%) instead of downregulated following CHD8 knockdown.
exclusive knockdown of narrowing, the list of differentially expressed genes due to CHD8 insufficiency in neural progenitor cells, which did not reach statistical significance for enrichment (P = 0.153, OR = 1.378). Again, considering only those genes that are downregulated significantly strengthened the enrichment (P = 0.038, OR = 1.673). In comparing all genes from the SFARI database and the narrow list of ASD genes, upregulated genes fail to show significant enrichment in both the cases. These results suggest no advantage of narrowing the list of genes by evidence-based scoring. These results further suggest that CHD8 insufficiency may regulate a network of genes that contribute to ASD risk. Although previously identified ASD candidate genes are enriched among the 1715 differentially expressed genes following CHD8 knockdown, the magnitude of gene expression changes is similar between ASD candidate genes and genes not previously implicated in ASD. These results suggest that, in addition to altering expression of genes implicated in ASD, CHD8 knockdown also impacts expression of genes that are either unrelated to ASD or not yet identified as contributors to ASD risk.

**Table 2.** ASD-associated genes differentially expressed following knockdown of CHD8

| ASD-associated genea | Fold change | Locusb | Q-value |
|----------------------|-------------|---------|---------|
| HTR1B                | 4.22        | 678171947-78173120 | 3.54E-2 |
| CNTNAP4              | 1.88        | 1676311175-7593135 | 1.27E-2 |
| NBEA                 | 1.65        | 3153516423-36705514 | 1.05E-3 |
| CNTN4                | 1.63        | 312140549-3099645 | 1.05E-3 |
| ITGB3                | 1.55        | 1745331207-45390077 | 9.79E-3 |
| SYNE1                | 1.47        | 6152442818-152958534 | 1.05E-3 |
| STK39                | 1.28        | 2168810529-169104105 | 2.55E-2 |
| GTF2I               | −1.27       | 774072029-74175022 | 2.20E-2 |
| UBE2H                | −1.31       | 7129470572-129952800 | 7.70E-3 |
| RIMS5                | −1.34       | 141086351-41131324 | 4.08E-3 |
| CA1                  | −1.34       | 78152814-8302242 | 7.65E-3 |
| RPS6KA2              | −1.37       | 6166822853-167275771 | 1.92E-3 |
| NRXN2                | −1.38       | 1164373645-64490066 | 1.71E-2 |
| ADK                  | −1.39       | 1075910942-76469061 | 1.71E-2 |
| CEP41                | −1.40       | 7130033611-130081051 | 7.65E-3 |
| HDAC4                | −1.40       | 2239969863-240322643 | 1.12E-2 |
| NF1                  | −1.41       | 1729421944-29704695 | 3.40E-3 |
| TSPAN7               | −1.45       | X38420730-38548172 | 2.47E-2 |
| SCN2A                | −1.56       | 2166095911-166248820 | 1.05E-3 |
| REEP3                | −1.59       | 1065281122-65384883 | 1.05E-3 |
| CHRNA7               | −1.63       | 1532226685-32462384 | 1.92E-3 |
| OXTR                 | −1.66       | 38792094-8811300 | 1.40E-2 |
| NRP2                 | −1.68       | 2206547223-206662857 | 1.05E-3 |
| DHCR7                | −1.70       | 117145456-71539477 | 1.05E-3 |
| SEMA5A               | −1.81       | 59053157-9546233 | 1.05E-3 |
| KCNMA1               | −1.83       | 1078629358-79397577 | 1.05E-3 |
| NPSA5                | −2.45       | 2101436612-101613287 | 1.05E-3 |

Abbreviations: ASD, autism spectrum disorder; CHD8, chromodomain helicase DNA-binding protein 8. *According to genes within SFARI database possessing gene scores of ‘1–4’ and ‘5–7’. *Refers to UCSC Hg19.

SFARI gene rankings as previously described.25 Following this narrowing, the list of differentially expressed genes due to knockdown of CHD8 contained a total of 27 overlapping genes excluding CHD8 (Table 2), which did not reach statistical significance for enrichment (P = 0.153, OR = 1.378). Again, considering only those genes that are downregulated significantly strengthened the enrichment (P = 0.038, OR = 1.673). In comparing all genes from the SFARI database and the narrow list of ASD genes, upregulated genes fail to show significant enrichment in both the cases. These results suggest no advantage of narrowing the list of genes by evidence-based scoring. These results further suggest that CHD8 insufficiency may regulate a network of genes that contribute to ASD risk. Although previously identified ASD candidate genes are enriched among the 1715 differentially expressed genes following CHD8 knockdown, the magnitude of gene expression changes is similar between ASD candidate genes and genes not previously implicated in ASD. These results suggest that, in addition to altering expression of genes implicated in ASD, CHD8 knockdown also impacts expression of genes that are either unrelated to ASD or not yet identified as contributors to ASD risk.
observed for all differentially expressed genes. These include GO categories such as regulation of neuron differentiation, neurogenesis and neuron projection development (Figure 3b, Supplementary Table 10), all of which may be processes disrupted during ASD pathogenesis. In addition, utilizing the Uniprot tissue (UP_TISSUE) annotation database, we found the downregulated genes to be highly enriched in brain tissue \((P = 2.01 \times 10^{-15}, \text{Benjamini–Hotchberg correction})\), whereas upregulated genes were not enriched in any specific tissue (Supplementary Table 11). Overall, these results suggest that CHD8 retains conserved functions and also has an essential role in the maintenance of tissue-specific genes involved in neuron development.

CHD8 regulates a highly interconnected network of genes
To assess the connectivity among the differentially expressed genes following knockdown of CHD8, we utilized the Disease Association Protein–Protein Link Evaluator (DAPPLE). Analysis of all differentially expressed genes shows significant enrichment in both direct and indirect connectivity \((P = 3.00 \times 10^{-3} \text{ for both})\), identifying 2022 direct interactions (Figure 4, Supplementary Table 12). Analysis of the downregulated genes indicated a significant increase in indirect connectivity \((P = 9.99 \times 10^{-4} \text{ for indirect connectivity})\). Although upregulated genes showed no enrichment in ASD candidate genes and weak enrichment in GO categories, Disease

---

**Figure 3.** Representative enrichment of gene ontology among differentially expressed genes. (a) Gene ontology (GO) enrichment analysis on all differentially expressed genes due to knockdown of CHD8. (b) GO enrichment analysis on genes downregulated in response to knockdown of CHD8. Upreregulated genes subjected to GO analysis indicated enrichment of mitochondrial membrane genes only (not shown). \(P\)-value represents Benjamini–Hotchberg correction for multiple tests. CHD8, chromodomain helicase DNA-binding protein 8.

**Figure 4.** Protein–protein interaction analysis of differentially expressed genes—Disease Association Protein–Protein Link Evaluator (DAPPLE) was used to determine direct relationships among the protein products of the genes that were differentially expressed due to knockdown of CHD8. A subnetwork of genes with associated corrected \(P\)-values \(< 0.05\), indicating seed proteins that are more likely to be connected to other seed proteins within the network than by chance, was generated and visualized using Cytoscape software. Increasing significance corresponds to increasing node size. Differential expression of the associated gene product is shown with increasing densities of blue and red indicating the degree of down- and upregulation conferred by knockdown of CHD8, respectively. CHD8, chromodomain helicase DNA-binding protein 8.
Association Protein–Protein Link Evaluator showed an unexpected enrichment in direct and indirect connectivity among upregulated genes ($P = 2.00 \times 10^{-3}$ and $P = 3.20 \times 10^{-2}$, respectively). These results suggest a network of connected genes upregulated by CHD8.

**DISCUSSION**

From the initial discovery through exome sequencing to confirmation by targeted sequencing of additional ASD probands, *de novo* LoF mutations in CHD8 are highly implicated in contributing to ASD.\(^5\)\(^6\) Due to the heterogeneity of ASD, it is likely to be influenced by the combinatorial effects of hundreds of genes under abnormal regulation. Although genetic influences may vary among ASD cases, strong evidence suggests that the functional contribution of these various factors may converge on similar pathways.\(^4\)\(^8\)\(^9\) Our data suggest that CHD8 may be a central node in one of these pathways as CHD8 insufficiency in human neuronal progenitor cells results in altered expression of previously identified ASD candidate genes. Among recently identified genes disrupted in autism,\(^29\) CACNA2D3 and ETFB were among the 1715 genes with altered expression following CHD8 knockdown, suggesting potential biological pathways that contribute to ASD.

Considering the enrichment of ASD candidate genes among the differentially expressed protein-coding genes, the ncRNA genes identified in our analysis may also serve as contributing factors to ASD phenotypes. The ncRNA represents a relatively unexplored category of genes that participate in several regulatory functions and may potentially contribute to the neurodevelopmental phenotypes observed in ASD.\(^26\)\(^29\)\(^30\)\(^31\) For example, the ncRNAs colorectal neoplasia differentially expressed (CRNDE) and telomerase RNA component, have both been shown to undergo differential expression during neuronal differentiation of pluripotent stem cells suggesting their participation in neurogenesis.\(^32\)\(^33\) In particular, CRNDE is intimately linked with the insulin/IGF signaling pathway, as treatment with IGF1 or IGFB2 downregulates nuclear-retained CRNDE transcripts.\(^34\) This is of importance to ASD as administration of IGF1 has been shown to rescue phenotypes associated with Rett Syndrome\(^75\)\(^76\) and is now in clinical trials.\(^37\) Our findings of upregulation of CRNDE following decreased expression of CHD8 suggest that this ncRNA may represent a novel therapeutic target. In addition, our data shows down-regulation of the ncRNA TUG1, which has been shown to directly associate with the chromatin modifying complex, PRC2, and to be regulated by p53.\(^38\) This may represent a novel ncRNA target of CHD8, as CHD8 is known to interact with p53 and colocalize to promoters of p53-regulated genes.\(^11\)

Consistent with previous studies showing the participation of CHD8 in large protein complexes involving members of the mixed lineage leukemia (MLL) family,\(^40\) depletion of endogenous CHD8 in neural cells results in decreased expression of the MLL genes, MLLT1 and MLLT3, along with *MNN1*, which associates with MLL to regulate transcription.\(^40\) In addition, our data show the conservation of specific changes in gene expression including genes involved in Wnt signaling (*DIKK1* and *NKD2*) and the p53 target, *CDKN1A*. In CHD8-depleted HCT116 colorectal cancer cells and U2OS osteosarcoma cells, respectively.\(^1,^47\) Approximately 13% of differentially expressed genes in our analysis of human neural progenitor cells were shown to have CHD8 bound to their promoters in previous work characterizing the binding sites of CHD8 in human C33A cervical carcinoma cells (Supplementary Table 13).\(^14\) Although these data point toward the conservation of specific regulatory mechanisms involving CHD8, our analyses also suggest a tissue-specific function of CHD8 in maintaining the active transcription of genes related to neuronal development. This is illustrated by the significant enrichment of neuron-development GO categories, brain tissue specificity and the significant connectivity of genes down-regulated by CHD8 insufficiency. In contrast, upregulated genes lack tissue enrichment, suggesting that they are not specific to any particular tissue type.

Sugathan et al.\(^42\) recently described the binding sites of CHD8 and changes in transcription resulting from knockdown of CHD8 in iPSC-derived neuronal progenitor cells where they found CHD8 to be localized to 5568 promoters and 1756 differentially expressed genes, respectively. Comparing the Sugathan et al.\(^42\) list of differentially expressed genes with the list of 1715 genes observed in the current study, there is an overlap of 159 genes (9.37%, Supplementary Table 14). There were 633 (37.30%) differentially expressed genes in our data set that Sugathan et al.\(^42\) reported to have CHD8 bound in close proximity to the transcription start site (Supplementary Table 15), indicating that there is a substantial proportion of genes directly regulated by CHD8. In addition, the differentially expressed genes that are shared between our data and that of Sugathan et al.\(^42\) include HIF10, TP53INP1 and MLLT3, suggesting conserved functions of CHD8 to participate in protein complexes containing members of the MLL family\(^39\) and regulate p53 signaling through interactions with Histone H1.\(^11\) As we also find CHD8 knockdown results in an enrichment of differentially expressed ASD-associated genes, this illustrates the involvement of CHD8 in regulating neurodevelopmental genes, which may differ between cell types and emphasizes the need for these transcriptional networks to be analyzed in several cellular models.

Our data indicate that a decrease of functional CHD8 in human neuronal progenitor cells induces numerous transcriptional changes that potentially contribute to the pathogenesis of ASD. As the goal of this study was to uncover the consequences of CHD8 insufficiency as a whole rather than each of the particular CHD8 LoF mutations identified in individual patients, the modeling of the exact CHD8 LoF mutations through genome-editing techniques or induced pluripotent stem cell generation should be considered a priority. With the function of CHD8 in neurons just beginning to be explored, this work lays a foundation for further functional studies and identifies numerous molecular targets, including targetable ncRNAs, that could potentially be modulated for the purposes of therapeutic intervention.

**CONFLICT OF INTEREST**

The authors declare no conflict of interest.

**ACKNOWLEDGMENTS**

This work was supported by the US National Institutes of Health grants R01MH1100172 to DBC and R21MH099504 to DBC.

**REFERENCES**

1. American Psychiatric Association and American Psychiatric Association DSM-5 Task Force. *Diagnostic and Statistical Manual of Mental Disorders*: DSM-5. American Psychiatric Association: Arlington, VA, USA, 2013.
2. Krumm N, O’Roak BJ, Shendure J, Eichler EE. A de novo convergence of autism genetics and molecular neuroscience. *Trends Neurosci* 2014; 37: 95–105.
3. Jeste SS, Geschwind DH. Disentangling the heterogeneity of autism spectrum disorder through genetic findings. *Nat Rev Neurol* 2014; 10: 74–81.
4. Levitt P, Campbell DB. The genetic and neurobiologic compass points toward common signaling dysfunctions in autism spectrum disorders. *J Clin Invest* 2009; 119: 747–754.
5. Sanders S, Murtha MT, Gupta AR, Murdoch JD, Raubeson MJ, Willsey AJ et al. De novo mutations revealed by whole-exome sequencing are strongly associated with autism. *Nature* 2012; 485: 237–241.
6. O’Roak BJ, Vives L, Gitiranjain S, Karakoc E, Krumm N, Coe BP et al. Sporadic autism exomes reveal a highly interconnected protein network of de novo mutations. *Nature* 2012; 485: 246–250.
7. Neale BM, Kou Y, Liu L, Ma’ayan A, Samocha KE, Sabo A et al. Patterns and rates of exonic de novo mutations in autism spectrum disorders. *Nature* 2012; 485: 242–245.
8 O’Roak BJ, Vives L, Fu W, Egertson JD, Stanaway IB, Phelps IG et al. Multiplex targeted sequencing identifies recurrently mutated genes in autism spectrum disorders. Science 2012; 338: 1619–1622.

9 Bernier R, Golzi C, Xiong B, Stessman HA, Coe BP, Penn O et al. Disruptive CHD8 mutations define a subtype of autism early in development. Cell 2014; 158: 236–237.

10 Talkowski ME, Rosenfeld JA, Blumenthal J, Pillalamarri V, Chiang C, Heibout A et al. Sequencing chromosomal abnormalities reveals neurodevelopmental loci that confer risk across diagnostic boundaries. Cell 2012; 149: 525–537.

11 Nishiyama M, Oshikawa K, Tsukada Y, Nakagawa T, Iemura S, Natsume T et al. CTCF-dependent chromatin insulator is linked to epigenetic remodeling. Mol Cell 2006; 23: 733–742.

12 Rodríguez-Paredes M, Ceballos-Chávez M, Esteller M, García-Dominguez M, Reyes JC. The chromatin remodeling factor CHD8 interacts with elongating RNA polymerase II and controls expression of the cyclin E2 gene. Nucleic Acids Res 2007; 37: 2449–2460.

13 Ishihara K, Oshimura M, Nakao M. CTCF-dependent chromatin insulator is linked to epigenetic remodeling. Mol Cell 2006; 23: 733–742.

14 Subol-Rodríguez A, Vázquez-Chávez E, Ceballos-Chávez M, Rodríguez-Paredes M, Martín-Subero JJ, Esteller M et al. The chromatin remodeler CHD8 is required for EZF-dependent transcription activation of S-phase genes. Nucleic Acids Res 2014; 42: 2185–2196.

15 Yates JA, Menon T, Thompson BA, Bochar DA. Regulation of HOXA2 gene expression by the ATP-dependent chromatin remodeling enzyme CHD8. FEBS Lett 2010; 584: 689–693.

16 Caldon CE, Sergio CM, Schütte J, Boesma MN, Sutherland RL, Carroll JS et al. Estrogen regulation of cyclin E2 requires cyclin D1 but not c-Myc. Mol Cell Biol 2009; 29: 4623–4639.

17 Martin M. Cidaptad removes adapter sequences from high-throughput sequencing reads. EMNet J 2011; 17: pp 10–12.

18 Kim D, Pertea G, Trapnell C, Fritsche H, Kelley R, Salzberg SL. TopHat2: accurate alignment of transcriptomes in the presence of insertions, deletions and gene fusions. Genome Biol 2013; 14: R36.

19 Trapnell C, Roberts A, Goff L, Pertea G, Kim D, Kelley DR et al. Differential gene and transcript expression analysis of RNA-seq experiments with TopHat and Cufflinks. Nat Protoc 2012; 7: 562–578.

20 Schmittgen TD, Livak KJ. Analyzing real-time PCR data by the comparative C (T) method. Nat Protoc 2008; 3: 1101–1108.

21 Dennis G, Sherman BT, Hosack DA, Yang J, Gao W, Lane HC et al. DAVID: Database for Annotation, Visualization, and Integrated Discovery. Genome Biol 2003; 4: P3.

22 Rossin EJ, Lage K, Raychaudhuri S, Xavier RJ, Tatar D, Benita Y et al. Proteins encoded in genomic regions associated with immune-mediated disease physically interact and suggest underlying biology. PLoS Genet 2011; 7: e1001273.

23 Shannon P, Markiel A, Ozier O, Baliga NS, Wang JT, Ramage D et al. Cytoscape: a software environment for integrated models of biomolecular interaction networks. Genome Res 2003; 13: 2498–2504.

24 Abrahams BS, Arking DE, Campbell DB, Mefford HC, Morrow EM, Weiss LA et al. SFARI Gene 2.0: a community-driven knowledgebase for the autism spectrum disorders (ASDs). Mol Autism 2013; 4: 36.

25 Parkishak NN, Luo R, Zhang A, Won H, Lowe JK, Chandran V et al. Integrative functional genomic analyses implicate specific molecular pathways and circuits in autism. Cell 2013; 155: 1008–1021.

26 Wilkinson B, Campbell DB. Contribution of long noncoding RNAs to autism spectrum disorder risk. Int Rev Neurobiol 2013; 113: 35–59.

27 Menon T, Yates JA, Bochar DA. Regulation of androgen-responsive transcription by the chromatin remodeling factor CHD8. Mol Endocrinol 2010; 24: 1165–1174.

28 Berg JM, Geschwind DH. Autism genetics: searching for specificity and convergence. Genome Biol 2012; 13: 247.

29 De Rubeis S, He X, Goldberg AP, Poulton CS, Samocha K, Cicek AE et al. Synaptic, transcriptional and chromatin genes disrupted in autism. Nature 2014; 515: 209–215.

30 Kerin T, Ramanathan A, Rivas K, Grego N, Coetzee GA, Campbell DB. A noncoding RNA antisense to moesin at 14q11.1 in autism. Sci Transl Med 2012; 4: 128ra40.

31 Zsáts MN, Rennert OM. Abrupt expression of long noncoding RNAs in autistic brain. J Mol Neurosci 2013; 49: 589–593.

32 Lin M, Pedrosa E, Shah A, Hrabovsky A, Macboul S, Zheng D et al. RNA-Seq of human neurons derived from iPSC cells reveals candidate long non-coding RNAs involved in neurogenesis and neuropsychiatric disorders. PLoS One 2011; 6: e23356.

33 Ng SY, Johnson R, Stanton LW. Human long non-coding RNAs promote pluripotency and neuronal differentiation by association with chromatin modifiers and transcription factors. EMBO J 2012; 31: 522–533.

34 Ellis BC, Graham LD, Mollov PL. CRNDE, a long non-coding RNA responsive to insulin/IGF signaling, regulates genes involved in central metabolism. Biochim Biophys Acta 2014; 1843: 372–386.

35 Marchetto MC, Carromeu C, Acab A, Yu D, Yeo GW, Mu Y et al. A model for neural development and treatment of Rett syndrome using human induced pluripotent stem cells. Cell 2010; 143: 527–539.

36 Tropea D, Giaconetti E, Wilson NR, Beard C, McCurry C, Fu DD et al. Partial reversal of Rett Syndrome-like symptoms in MeCP2 mutant mice. Proc Natl Acad Sci USA 2009; 106: 2029–2034.

37 Khwaja OS, Ho E, Barnes KV, O’Leary HM, Pereira LM, Finkelstein Y et al. Safety, pharmacokinetics, and preliminary assessment of efficacy of mecasermin (recombinant human IGF-1) for the treatment of Rett syndrome. Proc Natl Acad Sci USA 2014; 111: 4596–4601.

38 Khull AM, Guttman M, Huarte M, Garber M, Raj A, Rice Morales D et al. Many human large intergenic noncoding RNAs associate with chromatin-modifying complexes and affect gene expression. Proc Natl Acad Sci USA 2009; 106: 11667–11672.

39 Dou Y, Milne TA, Tackett AJ, Smith ER, Fukuda A, Wysocka J et al. The chromatin remodeling factor that regulates beta-catenin target genes. EMBO J 2010; 29: 2460–2476.

40 Lin M, Pedrosa E, Shah A, Hrabovsky A, Macboul S, Zheng D et al. RNA-Seq of human neurons derived from iPSC cells reveals candidate long non-coding RNAs involved in neurogenesis and neuropsychiatric disorders. PLoS One 2011; 6: e23356.

41 Thompson BA, Tremblay V, Lin G, Bochar DA. CHD8 is an ATP-dependent chromatin modifier that regulates beta-catenin target genes. Mol Cell Biol 2009; 28: 3894–3904.

42 Sugathan A, Biagioli M, Golzio C, Erdin S, Blumenthal I, Manavalan P et al. CHD8 regulates neurodevelopmental pathways associated with autism spectrum disorder in neural progenitors. Proc Natl Acad Sci USA 2014; 111: E4468–E4477.

Supplementary Information accompanies the paper on the Translational Psychiatry website (http://www.nature.com/tp)